2025-522640-41-00
EU Clinical Trials Information System
- Trial ID
- T-ctis-2025-522640-41-00
- Registry
- EU Clinical Trials Information System
- CTIS number
- 2025-522640-41-00
- Sponsor, as registered
- Eli Lilly & Co.
- Phase
- Therapeutic exploratory (Phase II)
- Indication
- Uncontrolled moderate to severe asthma
- Status
- Authorised
- Start date
- 13/02/2026
- Primary completion
- CTIS does not publish one.
- Member states concerned
- Germany, France, Netherlands, Poland
- Sites
- 29
Member states whose regulator has a decision on this trial.
euclinicaltrials.euctis registryverified 2026-09-15
Notes on the record
countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded. J2S-MC-GZMR: Phase 2, multicentre, randomised, double-blind, 52-week, brenipatide (LY3537031) vs placebo. Member state decisions: DE 2026-01-21 authorized 9 sites; FR 2026-01-21 authorized 10; PL 2026-01-30 authorized 4; NL 2026-02-02 authorized_conditions 6. Start-of-recruitment notifications: PL 2026-02-18, DE 2026-03-05, FR 2026-04-23, NL 2026-07-13. publishDate 2026-09-14T16:55; lastUpdated 26/08/2026. Not among the five brenipatide records returned on 2026-08-24 (Issue 11); the API does not expose when it first became public. Outside the five records named in the Issue 12 call, so it does not score that call.
Company
Through brenipatide (LY3537031): Lilly
Cited in
Issues quoting 2025-522640-41-00 in their own text.